DelveInsight’s ‘Renal Tubular Acidosis Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Renal Tubular Acidosis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The Renal Tubular Acidosis market report provides analysis regarding current treatment practices, emerging drug-like ADV7103 (Advicenne), potential therapies, market share of the individual therapies, historical, current, and forecasted Renal Tubular Acidosis market size from 2017 to 2030 segmented by seven major markets.
The report also covers current Renal Tubular Acidosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Study Period: 2017–2030
Renal Tubular Acidosis Overview
Renal tubular acidosis (RTA) is a disease that occurs when the kidneys fail to excrete acids into the urine, which causes a person’s blood to remain too acidic. The term renal tubular acidosis (RTA) is applied to a group of transport defects in the reabsorption of bicarbonate (HCO3−), the excretion of hydrogen ion (H+), or both. This condition was first described in 1935, confirmed as a renal tubular disorder in 1946, and designated “renal tubular acidosis” in 1951.
RTA defines a class of disorders in which excretion of hydrogen ions or reabsorption of filtered bicarbonate is impaired, leading to a chronic metabolic acidosis with a normal anion gap. Symptoms may vary for different types of distal renal tubular acidosis; some commonly shown symptoms are as follows: confusion or decreased alertness, fatigue, impaired growth in children, increased breathing rate, kidney stones, Nephrocalcinosis (too much calcium deposited in the kidneys), Osteomalacia (softening of the bones) and muscle weakness.
This chapter covers the details of conventional and current medical therapies available in the Renal Tubular Acidosis market for the treatment of the condition. It also provides the country-wise Renal Tubular Acidosis treatment guidelines across the United States, Europe, and Japan.
DelveInsight’s Renal Tubular Acidosis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Renal Tubular Acidosis treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The Renal Tubular Acidosis epidemiology chapters provide insights about historical and current Renal Tubular Acidosis patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Renal Tubular Acidosis epidemiology is segmented by Total prevalent cases of Renal Tubular Acidosis, Cases of Renal Tubular Acidosis by gender, Cases of Renal Tubular Acidosis by Age, Cases of Distal Renal Tubular Acidosis by Types and Type-specific Renal Tubular Acidosis cases. The report includes a thorough analysis of all segmentations.
In the US, the cases of Renal Tubular Acidosis were 45,601 in 2017. Moreover, the Type-specific cases of Renal Tubular Acidosis were highest among Type 1 (distal RTA) and were reported to be 20,064 in the country.
According to DelveInsight’s analysis, the total prevalent population of Renal Tubular Acidosis in seven major markets was 1,08,679 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
Among all the seven major markets, the United States accounts for the highest number of Renal Tubular Acidosis cases.
The drug chapter segment of the Renal Tubular Acidosis report encloses the detailed analysis of Renal Tubular Acidosis pipeline drug. It also helps understand the Renal Tubular Acidosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
The aim is not only to correct the biochemical abnormalities but to fundamentally improve growth in children and to prevent the progression of nephrocalcinosis and the development of chronic renal failure at all ages. The basis of therapy is the continuous administration of appropriate amounts of alkali in the form of either bicarbonate or citrate. The amount of alkali administered should compensate for the urinary loss of HCO3− plus the amount of acid generated by the catabolism of proteins and the skeletal growth. There is just a single therapy in the pipeline for treating individuals with RTA.
The Renal Tubular Acidosis market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Renal Tubular Acidosis market size, with USD 6.2 million in 2017, while Spain had the smallest market size of Renal Tubular Acidosis with USD 0.9 million in 2017.
This section focusses on the rate of uptake of the potential drugs in the Renal Tubular Acidosis market that are expected to get launched in the market during the study period 2017–2030. The analysis covers Renal Tubular Acidosis market uptake by drugs, patient uptake by therapies, and sale of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Renal Tubular Acidosis market is anticipated to experience a positive shift in the coming years owing to the expected launch of emerging therapies.
Renal Tubular Acidosis Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Renal Tubular Acidosis key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of Renal Tubular Acidosis collaborations, acquisition and merger, licensing, patent details, and other information for Renal Tubular Acidosis emerging therapies.
Approaching reimbursement, proactively, can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME’s opinion working in Renal Tubular Acidosis domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Renal Tubular Acidosis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
Which geography accounted for the largest Renal Tubular Acidosis market size?
The United States accounted for the largest Renal Tubular Acidosis market size.
What is forecasted Renal Tubular Acidosis market size in 2030?
DelveInsight estimates an increase in Renal Tubular Acidosis Market Size during the study period, 2017–2030
What is the present Renal Tubular Acidosis market drivers?
Increasing opportunities and organizational support.
What is the Renal Tubular Acidosis market barriers?
Drawbacks in the standard of care and focus on single disease outcomes are likely to block the market growth.
How many companies are developing drugs for Renal Tubular Acidosis?
Currently, there is only one key pharma player engaged in developing the drug for Renal Tubular Acidosis.
Which are the leading companies in the Renal Tubular Acidosis market?
Key Player- Advicenne
How is epidemiology segmented for Renal Tubular Acidosis?
Prevalent Cases of Renal Tubular Acidosis, Renal Tubular Acidosis cases by Gender, Cases of RTA by Age, Cases of Distal Renal Tubular Acidosis by Types and Type-specific cases of RTA.
1 Key Insights
2 Executive Summary of Renal Tubular Acidosis
3 SWOT Analysis for Renal Tubular Acidosis
4 Renal Tubular Acidosis Market Overview at a Glance
4.1 Market Share (%) Distribution of Renal Tubular Acidosis in 2017
4.2 Market Share (%) Distribution of Renal Tubular Acidosis in 2030
5 Disease Background and Overview
5.1 Introduction
5.2 Types of Renal Tubular Acidosis
5.3 Sign and Symptoms
5.4 Clinical Manifestations
5.5 Causes
5.6 Pathophysiology
5.7 Diagnosis
6 Epidemiology and Patient Population
6.1 Key Findings
6.2 7MM Total Prevalent Patient Population of Renal Tubular Acidosis
7 Country Wise-Epidemiology of Renal Tubular Acidosis
7.1. Assumptions and Rationale – 7MM
7.2 The United States
7.2.1 Total Prevalent Cases of Renal Tubular Acidosis in the United States
7.2.2 Type-specific Cases of Renal Tubular Acidosis in the United States
7.2.3 Age-specific Cases of Renal Tubular Acidosis in the United States
7.2.4 Cases of Distal Renal Tubular Acidosis by Types in the United States
7.2.5 Gender-specific Cases of Renal tubular Acidosis in the United States
7.3 EU5
7.4 Germany
7.4.1 Total Prevalent Cases of Renal Tubular Acidosis in Germany
7.4.2 Type-specific Cases of Renal Tubular Acidosis in Germany
7.4.3 Age-specific Cases of Renal Tubular Acidosis in Germany
7.4.4 Cases of Distal Renal Tubular Acidosis by Types in Germany
7.4.5 Gender-specific Cases of Renal tubular Acidosis in Germany
7.5 France
7.5.1 Total Prevalent Cases of Renal Tubular Acidosis in France
7.5.2 Type-specific Cases of Renal Tubular Acidosis in France
7.5.3 Age-specific Cases of Renal Tubular Acidosis in France
7.5.4 Cases of Distal Renal Tubular Acidosis by Types in France
7.5.5 Gender-specific Cases of Renal tubular Acidosis in France
7.6 Italy
7.6.1 Total Prevalent Cases of Renal Tubular Acidosis in Italy
7.6.2 Type-specific Cases of Renal Tubular Acidosis in Italy
7.6.3 Age-specific Cases of Renal Tubular Acidosis in Italy
7.6.4 Cases of Distal Renal Tubular Acidosis by Types in Italy
7.6.5 Gender-specific Cases of Renal tubular Acidosis in Italy
7.7 Spain
7.7.1 Total Prevalent Cases of Renal Tubular Acidosis in Spain
7.7.2 Type-specific Cases of Renal Tubular Acidosis in Spain
7.7.3 Age-specific Cases of Renal Tubular Acidosis in Spain
7.7.4 Cases of Distal Renal Tubular Acidosis by Types in Spain
7.7.5 Gender-specific Cases of Renal tubular Acidosis in Spain
7.8 The United Kingdom
7.8.1 Total Prevalent Cases of Renal Tubular Acidosis in the United Kingdom
7.8.2 Type-specific Cases of Renal Tubular Acidosis in the United Kingdom
7.8.3 Age-specific Cases of Renal Tubular Acidosis in the UK
7.8.4 Cases of Distal Renal Tubular Acidosis by Types in the UK
7.8.5 Gender-specific Cases of Renal tubular Acidosis in the United Kingdom
7.9 Japan
7.9.1 Total Prevalent Cases of Renal Tubular Acidosis in Japan
7.9.2 Type-specific Cases of Renal Tubular Acidosis in Japan
7.9.3 Age-specific Cases of Renal Tubular Acidosis in Japan
7.9.4 Cases of Distal Renal Tubular Acidosis by Types in Japan
7.9.5 Gender-specific Cases of Renal tubular Acidosis in Japan
8 Treatment
9 Unmet Needs
10 Organizations contributing toward Renal Tubular Acidosis
11 Case Reports
11.1 Renal Tubular Acidosis: As case Discussion in Japan
11.2 Renal Tubular Acidosis: As case discussion in the US
12 Emerging Therapies
12.1 ADV7103: Advicenne
12.1.1 Product Description
12.1.2 Other Development Activities
12.1.3 Clinical Development
12.1.4 Safety and Efficacy
13 Renal Tubular Acidosis: 7 Major Market Analysis
13.1 Key Findings
13.2 Market Size of Renal Tubular Acidosis in 7MM
14 Market Outlook
14.1 7MM Market Outlook
14.1.1 United States Market Size
14.2 EU-5 Countries: Market Outlook
14.2.1 Germany
14.2.2 France
14.2.3 Italy
14.2.4 Spain
14.2.5 United Kingdom
14.3 Japan: Market Outlook
14.3.1 Total Market Size of Renal Tubular Acidosis
14.3.2 Market Size of Renal Tubular Acidosis by Therapies
15 Market Drivers
16 Market Barriers
17 Appendix
17.1 Report Methodology
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
List of Tables
Table 1: Summary of Renal Tubular Acidosis Market, Epidemiology, and Key Events (2017–2030)
Table 2: Overview of Renal Tubular Acidosis
Table 3: Common causes of Renal Tubular Acidosis (RTA)
Table 4: Main genetic defects of distal renal tubular acidosis (dRTA) and their associated clinical manifestations
Table 5: Diagnostic tests to differentiate distal renal tubular acidosis from other types of renal tubular acidosis
Table 6: Prevalent Patient Population of Renal Tubular Acidosis in 7MM (2017–2030)
Table 7: Total Prevalent Cases of Renal Tubular Acidosis in the United States (2017–2030)
Table 8: Type-specific Cases of Renal Tubular Acidosis in the United States (2017–2030)
Table 9: Age-specific Cases of Renal Tubular Acidosis in the United States (2017–2030)
Table 10: Cases of Distal Renal Tubular Acidosis by Types in the United States (2017–2030)
Table 11: Gender-specific Cases of Renal tubular Acidosis in the United States (2017–2030)
Table 12: Total Prevalent Cases of Renal Tubular Acidosis in Germany (2017–2030)
Table 13: Type-specific Cases of Renal Tubular Acidosis in Germany (2017–2030)
Table 14: Age-specific Cases of Renal Tubular Acidosis in Germany (2017–2030)
Table 15: Cases of Distal Renal Tubular Acidosis by Types in Germany (2017–2030)
Table 16: Gender-specific Cases of Renal tubular Acidosis in Germany (2017–2030)
Table 17: Total Prevalent Cases of Renal Tubular Acidosis in France (2017–2030)
Table 18: Type-specific Cases of Renal Tubular Acidosis in France (2017–2030)
Table 19: Age-specific Cases of Renal Tubular Acidosis in France (2017–2030)
Table 20: Cases of Distal Renal Tubular Acidosis by Types in France (2017–2030)
Table 21: Gender-specific Cases of Renal tubular Acidosis in France (2017–2030)
Table 22: Total Prevalent Cases of Renal Tubular Acidosis in Italy (2017–2030)
Table 23: Type-specific Cases of Renal Tubular Acidosis in Italy (2017–2030)
Table 24: Age-specific Cases of Renal Tubular Acidosis in Italy (2017–2030)
Table 25: Cases of Distal Renal Tubular Acidosis by Types in Italy (2017–2030)
Table 26: Gender-specific Cases of Renal tubular Acidosis in Italy (2017–2030)
Table 27: Total Prevalent Cases of Renal Tubular Acidosis in Spain (2017–2030)
Table 28: Type-specific Cases of Renal Tubular Acidosis in Spain (2017–2030)
Table 29: Age-specific Cases of Renal Tubular Acidosis in Spain (2017–2030)
Table 30: Cases of Distal Renal Tubular Acidosis by Types in Spain (2017–2030)
Table 31: Gender-specific Cases of Renal tubular Acidosis in Spain (2017–2030)
Table 32: Total Prevalent Cases of Renal Tubular Acidosis in the United Kingdom (2017–2030)
Table 33: Type-specific Cases of Renal Tubular Acidosis in the United Kingdom (2017–2030)
Table 34: Age-specific Cases of Renal Tubular Acidosis in the UK (2017–2030)
Table 35: Cases of Distal Renal Tubular Acidosis by Types in the UK (2017–2030)
Table 36: Gender-specific Cases of Renal tubular Acidosis in the United Kingdom (2017–2030)
Table 37: Total Prevalent Cases of Renal Tubular Acidosis in Japan (2017–2030)
Table 38: Type-specific Cases of Renal Tubular Acidosis in Japan (2017–2030)
Table 39: Age-specific Cases of Renal Tubular Acidosis in Japan (2017–2030)
Table 40: Cases of Distal Renal Tubular Acidosis by Types in Japan (2017–2030)
Table 41: Gender-specific Cases of Renal tubular Acidosis in Japan (2017–2030)
Table 42: Organizations contributing toward Renal Tubular Acidosis
Table 43: ADV7103, Clinical Trial Description, 2020
Table 44: Seven Major Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 45: United States Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 46: The US Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Table 47: Germany Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 48: Germany Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Table 49: France Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 50: France Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Table 51: Italy Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 52: Italy Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Table 53: Spain Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 54: Spain Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Table 55: United Kingdom Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 56: The UK Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Table 57: Japan Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Table 58: Japan Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
List of Figures
Figure 1: SWOT Analysis
Figure 2: Proximal Tubule Reabsorption of Bicarbonate
Figure 3: Acid Secretion in Collecting Duct
Figure 4: Algorithm to differentiate between normal anion gap metabolic acidosis owing to RTA
Figure 5: Algorithm for the clinical evaluation of non–anion gap metabolic acidosis
Figure 6: Diagnostic Approach to incomplete Distal RTA
Figure 7: Prevalent Patient Population of Renal Tubular Acidosis in 7MM (2017–2030)
Figure 8: Total Prevalent Cases of Renal Tubular Acidosis in the United States (2017–2030)
Figure 9: Type-specific Cases of Renal Tubular Acidosis in the United States (2017–2030)
Figure 10: Age-specific Cases of Renal Tubular Acidosis in the United States (2017–2030)
Figure 11: Cases of Distal Renal Tubular Acidosis by Types in the United States (2017–2030)
Figure 12: Gender-specific Cases of Renal tubular Acidosis in the United States (2017–2030)
Figure 13: Total Prevalent Cases of Renal Tubular Acidosis in Germany (2017–2030)
Figure 14: Type-specific Cases of Renal Tubular Acidosis in Germany (2017–2030)
Figure 15: Age-specific Cases of Renal Tubular Acidosis in Germany (2017–2030)
Figure 16: Cases of Distal Renal Tubular Acidosis by Types in Germany (2017–2030)
Figure 17: Gender-specific Cases of Renal tubular Acidosis in Germany (2017–2030)
Figure 18: Total Prevalent Cases of Renal Tubular Acidosis in France (2017–2030)
Figure 19: Type-specific Cases of Renal Tubular Acidosis in France (2017–2030)
Figure 20: Age-specific Cases of Renal Tubular Acidosis in France (2017–2030)
Figure 21: Cases of Distal Renal Tubular Acidosis by Types in France (2017–2030)
Figure 22: Gender-specific Cases of Renal tubular Acidosis in France (2017–2030)
Figure 23: Total Prevalent Cases of Renal Tubular Acidosis in Italy (2017–2030)
Figure 24: Type-specific Cases of Renal Tubular Acidosis in Italy (2017–2030)
Figure 25: Age-specific Cases of Renal Tubular Acidosis in Italy (2017–2030)
Figure 26: Cases of Distal Renal Tubular Acidosis by Types in Italy (2017–2030)
Figure 27: Gender-specific Cases of Renal tubular Acidosis in Italy (2017–2030)
Figure 28: Total Prevalent Cases of Renal Tubular Acidosis in Spain (2017–2030)
Figure 29: Type-specific Cases of Renal Tubular Acidosis in Spain (2017–2030)
Figure 30: Age-specific Cases of Renal Tubular Acidosis in Spain (2017–2030)
Figure 31: Cases of Distal Renal Tubular Acidosis by Types in Spain (2017–2030)
Figure 32: Gender-specific Cases of Renal tubular Acidosis in Spain (2017–2030)
Figure 33: Total Prevalent Cases of Renal Tubular Acidosis in the United Kingdom (2017–2030)
Figure 34: Type-specific Cases of Renal Tubular Acidosis in the United Kingdom (2017–2030)
Figure 35: Age-specific Cases of Renal Tubular Acidosis in the UK (2017–2030)
Figure 36: Cases of Distal Renal Tubular Acidosis by Types in the UK (2017–2030)
Figure 37: Gender-specific Cases of Renal tubular Acidosis in the United Kingdom (2017–2030)
Figure 38: Total Prevalent Cases of Renal Tubular Acidosis in Japan (2017–2030)
Figure 39: Type-specific Cases of Renal Tubular Acidosis in Japan (2017–2030)
Figure 40: Age-specific Cases of Renal Tubular Acidosis in Japan (2017–2030)
Figure 41: Cases of Distal Renal Tubular Acidosis by Types in Japan (2017–2030)
Figure 42: Gender-specific Cases of Renal tubular Acidosis in Japan (2017–2030)
Figure 43: Unmet Needs of Renal Tubular Acidosis
Figure 44: Seven Major Market Size of Renal Tubular Acidosis in USD Million (2017–2030)
Figure 45: Market Size of Renal Tubular Acidosis in the United States, USD Million (2017–2030)
Figure 46: The US Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 47: Market Size of Renal Tubular Acidosis in Germany, USD Million (2017–2030)
Figure 48: Germany Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 49: Market Size of Renal Tubular Acidosis in France USD Million (2017–2030)
Figure 50: France Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 51: Market Size of Renal Tubular Acidosis in Italy, USD Million (2017–2030)
Figure 52: Italy Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 53: Market Size of Renal Tubular Acidosis in Spain, USD Million (2017–2030)
Figure 54: Spain Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 55: Market Size of Renal Tubular Acidosis in the United Kingdom, USD Million (2017–2030)
Figure 56: The UK Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 57: Market Size of Renal Tubular Acidosis in Japan, USD Million (2017–2030)
Figure 58: Japan Market Size of Renal Tubular Acidosis by Therapies in USD Million (2017–2030)
Figure 59: Market Drivers
Figure 60: Market Barriers
Advicenne
